Effect of the association of 1-methyl-DL-tryptophan with paclitaxel on the expression of indoleamine 2,3-dioxygenase in cultured cancer cells from patients with breast cancer

Medical Oncology

Volumn 32, Issue 11, 2015, Pages

  Salvadori, Maria Letícia Baptista ^a   da Cunha Bianchi, Pedro Kastein Faria ^a   Gebrim, Luiz Henrique ^b   Silva, Renata Santos ^a   Kfoury, José Roberto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cancer associated therapy; Flow cytometry; IDO; In vitro treatment; Taxol ; Tryptophan catabolism

Indexed keywords

1 METHYL DEXTRO LEVO TRYPTOPHAN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; PACLITAXEL; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG; 1-METHYLTRYPTOPHAN; ANTINEOPLASTIC AGENT; TRYPTOPHAN;

ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; ENZYMOLOGY; GENE EXPRESSION REGULATION; METABOLISM; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; PACLITAXEL; TRYPTOPHAN; TUMOR CELLS, CULTURED;

EID: 84943381723     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-015-0694-8     Document Type: Article

References (18)

1. American cancer society. 2014. http://www.cancer.org/cancer/breastcancer/index. Accessed on 15 May 2014.
2. Barksdale AR, Bernard AC, Maley ME, Gellin GL, Kearney PA, Boulanger BR, Tsuei BJ, Ochoa JB. Regulation of arginase expression by T-helper II cytokines and isoproterenol. Surgery. 2004. doi:10.1016/2003.10.007.
3. Bekki K, Vogel H, Li W, Ito T, Sweeney C, Haarmann-Stemmann T, Matsumura F, Vogel CF. The aryl hydrocarbon receptor (AhR) mediates resistance to apoptosis induced in breast cancer cells. Pestic Biochem Physiol. 2015. doi:10.1016/j.pestbp.
4. 4+ T cells. Blood. 2005. doi:10.1182/2004-06-2089.
5. Bronte V, Serafini PS, Marigo I, Tosello V, Mazzoni A, Segal DM, Lowel M, Sutter G, Colombo MP, Zanovello P. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol. 2003. doi:10.4049/170.1.270.
6. Hou DY, Muller AJ, Sharma MD, Duhadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 2007. doi:10.1158/0008-5472.
7. Kohler BA, Ward E, Mccarthy BJ, Schymura MJ, Ries LAG, Eheman C, Jemal A, Anderson RN, Ajani UA, Edwards BK. Annual report to the nation on the status of cancer, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 2011. doi:10.1093/jnci/djr077.
8. Munn DH, Mellor LA. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013. doi:10.1016/j.it.2012.10.001.
9. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL. Expression of IDO by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Investig. 2004. doi:10.1172/JCI200421583.
10. Munn DH. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol. 2006. doi:10.1016/2006.01.002.
11. Ng VG, Mena C, Pietras C, Lansky AJ. Local delivery of paclitaxel in the treatment of peripheral arterial disease. Eur J Clin Investig. 2015. doi:10.1111/eci.12407.
12. Platten M, Wick W, Optiz C. Immune modulation by tryptophan metabolism: relevance for autoimmune and tumor diseases. Dtsch Med Wochenschr. 2013. doi:10.1055/s-0033-1343222.
13. Potula R, Poluektova L, Knipe B, Chrastil J, Heilman D, Dou H, Takikawa O, Munn DH, Gendelman HE, Persidsky Y. Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in animal model of HIV-1 encephalitis. Blood. 2005. doi:10.1182/2005-04-1403.
14. Ruel-Gariépy E, Shive M, Bichara A, Berrada M, Le Garrec D, Chenite A, Leroux JC. A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel. Eur J Pharm Biopharm. 2004. doi:10.1016/S0939-6411(03)00095-X.
15. Schmidt SK, Siepmann S, Kuhlmann K, Meyer HE, Metzger S, Pudelko S, Leineweber M, Däubener W. Influence of tryptophan contained in 1-Methyl-Tryptophan on antimicrobial and immunoregulatory functions of indoleamine 2,3-dioxygenase. PLoS One. 2012. doi:10.1371/journal.pone.0044797.
16. Ueda S, Satoh T, Gotoh M, Gao L, Doi T. A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas. Oncologist. 2015. doi:10.1634/2014-0440.
17. Wang Y, Yang BH, Li H, Cao S, Ren XB, Yu JP. IDO(+) DCs and signalling pathways. Curr Cancer Drug Targets. 2013. doi:10.2174/15680096113139990073.
18. Ying W, Wang S, Shi J, Sun Y. ER-/ER + breast cancer cell lines exhibited different resistance to paclitaxel through pulse selection. Med Oncol. 2011. doi:10.1007/s12032-011-9889-9.